Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs PDR 001 (Primary) ; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ElevatION:NSCLC-101
- Sponsors Novartis Pharmaceuticals
- 19 Jul 2017 Planned End Date changed from 23 Oct 2019 to 6 Nov 2019.
- 19 Jul 2017 Planned primary completion date changed from 23 Oct 2019 to 6 Nov 2019.
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.